Codexis vs Gevo
Codexis (CDXS) and Gevo (GEVO) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $111M
- Last close
- $1.01
- 12 months
- −35.7%
- Market value
- $413M
- Last close
- $1.67
- 12 months
- −13.9%
At a glance
- The biggest part of Codexis's revenue is Research and development revenue (63%); at Gevo it is GevoND (85%).
- By market value, Gevo ($413M) is about 3.7 times Codexis ($111M).
- Over the last 12 months Codexis's share price moved −35.7% and Gevo's −13.9%; against the S&P 500 that is −41.4 points and −21.9 points.
- In their last fiscal years Codexis kept -62.5% of revenue as net income and Gevo -21.1%.
- In the last 90 days insiders reported 0 open-market purchases at Codexis and 2 at Gevo; members of Congress disclosed 0 trades in Codexis and 0 in Gevo.
- Next results: Codexis Mar 9, 2027, Gevo Mar 3, 2027.
How each one makes money: Codexis revenue · Gevo revenue
Share prices on one chart
Codexis and Gevo, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Codexis CDXSNASDAQ · Industrial Organic Chemicals | Gevo GEVONASDAQ · Industrial Organic Chemicals | |
|---|---|---|
| Size and profitability | ||
| Market value | $111M | $413M |
| Revenue, last fiscal year | $70.4M | $161M |
| Net income, last fiscal year | −$44M | −$33.8M |
| Net marginNet income as a share of revenue | -62.5% | -21.1% |
| Free cash flow | −$23.8M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Common questions
How is Codexis different from Gevo?
Codexis (CDXS) is in Industrial Organic Chemicals on NASDAQ, with $70.4M of revenue in its last fiscal year and a net margin of -62.5%. Gevo (GEVO) is in Industrial Organic Chemicals on NASDAQ, with $161M of revenue in its last fiscal year and a net margin of -21.1%. The biggest part of Codexis's revenue is Research and development revenue (63%); at Gevo it is GevoND (85%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Codexis and Gevo compare in size?
Gevo has the larger market value: Codexis $111M and Gevo $413M, at the last close.
Whose share price rose more over the last 12 months, CDXS or GEVO?
Over the last 12 months Codexis moved −35.7% and Gevo −13.9%. Past price moves say nothing about the future.
Which has had more insider buying, Codexis or Gevo?
Since 2006, Codexis insiders reported 78 open-market purchases against 38 for Gevo. These are counts of what was filed, not a view on either stock.
Do members of Congress trade CDXS or GEVO?
In the last 12 months, members of Congress disclosed 0 trades in Codexis (CDXS) and 0 in Gevo (GEVO).
When did insiders last buy CDXS and GEVO?
Codexis: Aug 4, 2025. Gevo: Aug 24, 2026.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Codexis pageGevo pageRare insider trades this weekAll comparisons
https://oqro.io/compare/cdxs-vs-gevo

